BN Business News
Bedrijf toevoegen →
Deze vertaling wordt voorbereid. Voorlopig tonen we de oorspronkelijke Engelse versie.

Bedrijven · 6-11-20031 min lezen

Determination That Hyaluronidase For Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

Lokale automatische vertaling · Oorspronkelijke brontaal

Samenvatting

The Food and Drug Administration (FDA) is announcing its determination that hyaluronidase for injection (Wydase) was not withdrawn from sale for reasons of safety or effectiveness. While this determination will allow FDA to approve abbreviated new drug applications (ANDAs) for hyaluronidase for injection, in considering whether to file an ANDA for this product, future applicants are advised that such an application raises complex issues regarding the characterization of the active ingredient.

Oorspronkelijke brontaal: Federal Register — Food and Drug AdministrationOrigineel bericht openen →